Replicating viral vector platform exploits alarmin signals for potent CD8⁺ T cell-mediated tumour immunotherapy.

ABSTRACT: Viral infections lead to alarmin release and elicit potent cytotoxic effector T lymphocyte (CTL^eff) responses. Conversely, the induction of protective tumour-specific CTL^eff and their recruitment into the tumour remain challenging tasks. Here we show that lymphocytic choriomeningitis virus (LCMV) can be engineered to serve as a replication competent, stably-attenuated immunotherapy vector (artLCMV). artLCMV delivers tumour-associated antigens to dendritic cells for efficient CTL priming. Unlike replication-deficient vectors, artLCMV targets also lymphoid tissue stroma cells expressing the alarmin interleukin-33. By triggering interleukin-33 signals, artLCMV elicits CTL^eff responses of higher magnitude and functionality than those induced by replication-defi

SUBMITTER: Kallert SM 

PROVIDER: S-EPMC5458557 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature